language
Language
Englishchevron_right
attach_money
Currency
$USDchevron_right
dark_mode
Dark Mode
policy
Privacy Policy
gavel
Terms of Service
HUMHUM

$241.59

+1.11
arrow_drop_up0.46%
Current Market·update13 Nov 2025 18:03
Day's Range
237.85-242.92
52-week Range
206.87-315.35

Chart

Loading chart...

Performance

Key Stats

Next Earnings Date2025-11-05
Next Earnings TimeBefore Market Open
Volume524.32K
Average Volume 30d1.83M

AI HUM Summary

Powered by LiveAI
💰
25.5
Valuation (P/E Ratio)
Reasonable for growth sector
📈
0.152
EPS Growth (YoY)
Strong earnings growth
Show More 🔒

AI Scoreboard

Powered by LiveAI
🔒

Overall Analysis

Buy
75

Humana Inc. presents a mixed investment profile. It demonstrates strong underlying fundamentals with robust revenue and a stable market position in the healthcare sector. However, recent profitability concerns and a slightly elevated valuation, coupled with mixed technical indicators, suggest a cautious approach is warranted. The company is well-positioned for long-term growth, particularly in government-sponsored health plans, but short-to-medium term performance may be impacted by regulatory changes and market sentiment.

Strong

Thematic

80

Humana is well-positioned to benefit from several key secular trends in the healthcare industry, including the aging population, increasing demand for managed care, and government healthcare spending (Medicare Advantage, Medicaid). Their focus on integrated care models and pharmacy benefits through CenterWell offers diversification and growth potential.

Good

Fundamental

78

Humana demonstrates strong revenue growth and a solid balance sheet. However, profitability has shown volatility, with a recent dip in net income and margins. The P/E ratio is within a reasonable range for the healthcare sector, but the dividend yield is modest.

Neutral

Technical

68

The stock is trading below its 50-day and 200-day moving averages, indicating a bearish short-to-medium term trend. While some oscillators suggest oversold conditions, others show neutral to bearish momentum, pointing to potential sideways movement or further declines before a sustained recovery.

FactorScore
Aging Population & Healthcare Demand90
Government Healthcare Programs (Medicare/Medicaid)85
Integrated Care & Pharmacy Services (CenterWell)88
Healthcare Technology & Digitalization70
Regulatory & Policy Environment65
FactorScore
Valuation70
Profitability45
Growth75
Balance Sheet Health70
Cash Flow75
Dividends60
FactorScore
Trend Analysis40
Momentum55
Volume Confirmation65
Support & Resistance70
Short-term Oscillators60

AI Investing Checklist

Powered by LiveAI
thumb_up

Bullish Points (7)

Earnings Performance chevron_right

Positive EPS Surprises

The company has exceeded earnings per share (EPS) estimates in 9 out of the last 12 quarters, with an average surprise of 10.4%. This consistent beat indicates strong operational execution and forecasting accuracy.

Valuation chevron_right

Attractive P/E Ratio

The trailing twelve-month (TTM) Price-to-Earnings (P/E) ratio is 16.18, which is lower than the industry average of 20.5, suggesting the stock may be undervalued relative to its earnings.

Show More 🔒
thumb_down

Bearish Points (7)

Earnings Performance chevron_right

Recent Earnings Miss

The company missed the EPS estimate in Q4 2024 by a significant margin (-174.23%), reporting -$0.11 against an estimate of $0.15. This recent miss suggests potential challenges in the current operating environment.

Valuation Risk chevron_right

Elevated Price-to-Sales (P/S) Ratio

The P/S ratio for the trailing twelve months (TTM) is 0.3, and it was 0.3 for 2024, 2023, and 2022. While consistent, this ratio should be compared against industry peers to determine if it represents value or overvaluation given the revenue scale.

Show More 🔒

Calendar

June 2025

27

Ex-Dividend Date

July 2025

25

Next Dividend Date

July 2025

30

Next Earnings Date

EPS Est.
Revenue Est.

H: $8.28

A: $5.87

L: $4.50

H: 32.35B

A: 31.85B

L: 31.53B

Profile

Websitehumana.com
Employees (FY)65.7K
ISINUS4448591028
FIGI-

Humana Inc. provides medical and specialty insurance products in the United States. It operates in two segments, Insurance and CenterWell. It offers medical care and supplemental benefit plans to individuals. The company also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, it provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits, as well as administrative services only products to individuals and employer groups; and military services, such as TRICARE T2017 East Region contract. Further, the company engages in the operation of pharmacy benefit manager business; operates pharmacies and senior focused primary care centers; and offers home solutions services, such as home health, hospice, and other services to its health plan members, as well as to third parties. It sells its products through employers and employees, independent brokers and agents, sales representatives, and digital insurance agencies. The company was formerly known as Extendicare Inc. and changed its name to Humana Inc. in April 1974. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.

Seasonals

2025
2024
2023
2022
2021

Price Target

286.44 USD

The 39 analysts offering 1 year price forecasts for HUM have a max estimate of 348.00 and a min estimate of 224.00.

Debt Level and Coverage

Debt
Free cash flow
Cash & equivalents

Financial Position Analysis

Assets
Liabilities

Ownership

Free Float shares
120M (99.81%)
Closely held shares
232K (0.19%)
121M
Free Float shares
120M (99.81%)
Closely held shares
232K (0.19%)

Capital Structure

Market cap
27.66B
Debt
11.72B
Minority interest
0.00
Cash & equivalents
2.22B
Enterprise value
37.16B

Valuation - Summary

Market Cap
27.7B
Net income
1.03B(3.73%)
Revenue
90.7B(327.94%)
27.7B
Market Cap
27.7B
Net income
1.03B(3.73%)
Revenue
90.7B(327.94%)
Price to earning ratio (P/E)26.80x
Price to sales ratio (P/S)0.30x

Valuation - Ratios

P/E
P/S

Revenue to Profit Conversion

Revenue
117.76B
COGS
117.76B
Gross Profit
0.00
OpEx
0.00
Operating Income
0.00
Other & Taxes
-1.21B
Net Income
1.21B

Balance Sheet

Total assets
Total liabilities
Liabilities to assets %

Income Statement

Revenue
Net Income
Net Margin

Cash Flow

Operating Cash Flow
Investing Cash Flow
Financing Cash Flow
Show More 🔒